Celldex Therapeutics, Inc. (NASDAQ: CLDX) will host a conference call before U.S. financial markets open at 8:30 a.m. Eastern Time on Wednesday, March 7, 2012, to provide a year-end summary for 2011 and an update on anticipated research and development and business objectives for 2012.
The conference call will be webcast live over the Internet and can be accessed by logging on to the Events Calendar under the "News & Events" section of the Celldex Therapeutics website at www.celldextherapeutics.com. The call can also be accessed by dialing 866-202-1971 (within the United States) or 617-213-8842 (outside the United States). The passcode for participants is 97699388.
A replay of the call will be available approximately two hours after the live call concludes through March 21, 2012. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode is 22360816. The webcast will also be archived on the Company’s website.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit http://www.celldextherapeutics.com.
Contacts:
Anthony S. Marucci, 781-433-0771
President
and CEO
or
Avery W. Catlin, 781-433-0771
Chief Financial
Officer
IR@celldextherapeutics.com
or
For
Media:
BMC Communications
Brad Miles, 212-477-9007 x17
brad@bmccommunications.com